Amphion Innovations plc

Sale of Partner Company Shares

London and New York, 19 March 2019 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that 3,250,000 shares in Partner Company, Motif Bio have been sold (“Sale”) in partial repayment of the loan facility (the “Facility”) originally announced on 5 June 2014 and most recently amended as announced on 11 March 2019 (“Amendment Agreement”).  Following this Sale, Amphion holds 20,179,611 ordinary shares of Motif Bio, representing 6.78% of the issued share capital.

The Sale generated proceeds of US $240,656. In accordance with the terms of the Amendment Agreement, two thirds of the sale proceeds will be used to reduce the loan balance under the Facility and one third of the remaining proceeds will be returned to the Company to be used for working capital. Further terms of the Amendment Agreement were included in the announcement on 11 March 2019.  The loan balance plus accrued interest will become due for repayment on 30 September 2019.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

---

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Emma Earl (Corporate Finance)
Charles Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

SP Angel Corporate Finance LLP (Joint Corporate Broker)
David Hignell (Corporate Finance)
Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.